Among the important figures, regularly communicated by the agency, there was 3 321 notifications temporary unavailability From drugs for human use, it is an improvement compared to the 3841 of 2023.
How to explain this 14 %drop? “”Many measures have been implemented by AFMPS, in collaboration with sector players and European partners. If certain shortages persist, especially for vital or pediatric treatments, the majority is now resolved quickly, alternatives are often available or recommendations are issued to treat patients at best“Said the agency in its press release.
And the side effects?
One of AFMPS’s mission is to identify the side effects of drugs. The agency has listed 6,791 notifications of undesirable effects concerning drugs for human use, a drop of 15 % compared to 2023.
The agency also announces that 3,766 postal parcels have been intercepted, containing non -compliant products from outside the European economic area.
The vigilance of the agency also relates to clinical trials: it approved 533 in 2024. And it manages the traceability of implants and medical devices: or 2809725 implantation and explantation notifications in 2024.
What are the side effects of hypertension drugs?
